The State Council's 2024 Legislative Plan mentions the draft Pharmacist Law in two places; According to statistics from April, the Central Commission for Discipline Inspection has named the management of different hospitals in at least four notices; Hebei Province issued the "Notice on the Bidding and Listing of Some Drugs", and from now on, some drugs that do not meet the conditions for listing will be cancelled......
Finishing | Uncle Mo
01
The State Council's legislative plan re-mentions the "Pharmacist Law"
On May 9, the General Office of the State Council issued the "State Council 2024 Legislative Plan", which mentions the draft of the Pharmacist Law in two places, and is again included in the "preliminary review" item.
It is understood that the draft of the Pharmacist Law was selected as a "preliminary review" project in 2021, 2023 and 2024 respectively, but it has not entered the formal review process for a long time.
It is worth noting that in this year's legislative plan, the "Draft Pharmacist Law" is ranked after the "Draft Medical Security Law", and last year it was ranked first.
02
The Central Commission for Discipline Inspection named pharmaceutical corruption, and many provinces followed up and rectified it
Recently, the website of the Central Commission for Discipline Inspection and the State Supervision Commission released the "Heilongjiang Reported 6 Typical Cases of Unhealthy Practices and Corruption Around the Masses", in which Ren, head of the Medical Insurance Section of Shuangyashan People's Hospital, illegally accepted financial problems from pharmaceutical companies and was transferred to the procuratorate for review and prosecution in accordance with the law.
The issue of corruption in the medical field has been reported again, and from April statistics alone, the website of the Central Commission for Discipline Inspection and the State Supervision Commission has named the management of different hospitals in at least 4 notices-
On May 10, the website of the Central Commission for Discipline Inspection and the State Supervision Commission announced that Xian Mou, the former president of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, was suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and supervision investigation by the Guangdong Provincial Commission for Discipline Inspection and Supervision.
On April 30, the website of the Central Commission for Discipline Inspection and the State Supervision Commission released the "Gansu Circular on 5 Typical Problems of Violating the Spirit of the Eight Regulations of the Central Committee", naming Wang Mou, the former president of Zhangye People's Hospital affiliated to Hexi University, for accepting banquets that may affect the fair performance of official duties, accepting gifts in violation of regulations, and accepting travel arrangements in violation of regulations.
03
If the price exceeds 1.8 times, it will not be hung on the net
Hundreds of varieties "strategic retreat" from Hebei
On May 7, the Hebei Provincial Medical Drugs and Devices Centralized Procurement Center issued the "Notice on the Bidding and Listing of Some Drugs", which will cancel the listing of some drugs that do not meet the conditions of the network from now on.
The withdrawal of the network is based on the online bidding policy issued by Hebei Province before: there are 2 or more chemical drug companies with the same generic name, the same dosage form and the same quality level, and the maximum price difference is generally not more than 1.8 times, and it is not higher than the lowest national online price of the company's drugs. Correspondingly, the maximum price difference between proprietary Chinese medicines and biological agents shall not exceed 3 times.
On April 22, Hebei has sorted out a list of drugs to be withdrawn from the network, most of which are generic drugs. Comparing the two lists before and after, only 11 varieties "escaped death", and the remaining hundreds of varieties will either be removed from the net if they have been hung or will not be hung up. The implementation of the "1.8 times price limit" mechanism is based on the rectification of "four same drugs". A large number of pharmaceutical companies may prefer to withdraw from the network in Hebei because they do not want to affect the national online price.
04
Centralized procurement of drugs that are prone to shortage and emergency rescue has landed in Fujian
On May 8, the Fujian Provincial Medical Insurance Bureau issued the "Notice on the Implementation of the Centralized Procurement and Use of Prone to Shortage and Emergency Rescue Drugs", clarifying that Fujian will implement the results of the centralized procurement of easy shortage and emergency rescue drugs on May 16, and the procurement cycle will in principle be from the date of implementation of the selection results to December 31, 2026.
There are 27 provinces such as Guangdong, Shanghai, Jiangsu, Zhejiang, and Fujian to form an alliance, and 17 clinically necessary and emergency rescue chemicals and therapeutic biological products are included in the centralized procurement.
For the first time, drugs that are prone to shortage and emergency rescue are procured, and the scope of participation in the alliance is very wide, and it is almost the scale of "small country procurement". The products covered by this centralized procurement include digoxin, aminophylline and other varieties, which are frequent customers on the "shortage list", and the price has risen greatly, which has attracted the attention of regulators.
05
This new domestic drug was approved for the first time
Recently, according to the official website of the State Food and Drug Administration, the Class 1 innovative drug Anectinib Fumarate Capsule (trade name: Ambernie) of Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceutical, a leading Hong Kong pharmaceutical company, was approved for marketing, marking a major breakthrough in the treatment of non-small cell lung cancer for domestic innovative drugs.
Anecutinib Fumarate Capsule is the first targeted drug for ROS1-positive non-small cell lung cancer in China, suitable for adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer.
Comprehensively compiled from: Chinese Government Network, Hebei Provincial Medical Drug and Device Centralized Procurement Center, Fujian Provincial Medical Insurance Bureau, Cyberblue, Xinkangjie
— END —